2‐(Allylthio)pyrazine, a Cancer Chemopreventive Agent, Inhibits Liver Fibrosis Induced by Dimethylnitrosamine in Rats: Role of Inhibition of Transforming Growth Factor‐β1 Expression

Abstract

Abstract: Exposure to nitrosamines may be the occupational risk factor for liver cirrhosis. 2‐(Allylthio)pyrazine, a chemopreventive agent, inhibits CYP2E1 and induces phase II enzymes. We examined the effects of 2‐(allylthio)pyrazine on hepatic fibrosis, a prepathologic state of cirrhosis, and on the expression of transforming growth factor‐β1 induced by dimethylnitrosamine. Treatment of rats with dimethylnitrosamine for 4 weeks increased plasma alanine/aspartate aminotransferase and γ‐glutamyl transpeptidase activities, and bilirubin content, whereas the total plasma protein and albumin levels were decreased. 2‐(Allylthio)pyrazine inhibited dimethylnitrosamine‐induced increases in the enzyme activities and bilirubin, and restored the plasma protein and albumin contents. Masson’s trichrome staining showed that dimethylnitrosamine induced liver fibrosis, the extent of which was reduced by 2‐(allylthio)pyrazine treatments. Reverse transcription‐polymerase chain reaction analysis revealed that 2‐(allylthio)pyrazine inhibited production of transforming growth factor‐β1 mRNA by dimethylnitrosamine. These results demonstrated that 2‐(allylthio)pyrazine might inhibit dimethylnitrosamine‐induced liver fibrosis due to suppression of CYP2E1 expression and transforming growth factor‐β1 production.